Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Aarhus University Hospital
Asparaginase treatment in acute lymphoblastic leukemia in children is jeopardized by a huge toxicity burden and the toxicities are often preventing further treatment. The most common asparaginase associated toxicities are hypersensitivity, pancreatitis, thromboembolism and osteonecrosis.
In the NOPHO ALL2008 protocol asparaginase associated toxicities have been registered since the protocol opened in July 2008. In addition asparaginase enzyme activity measurements have been done before every asparaginase administration and analyzed retrospectively.
This study evaluate the association between risk and severity of asparaginase associated toxicities and asparaginase enzyme activity levels in children with ALL treated in the NOPHO-ALL 2008 protocol.
Age
1–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
ALL, standard or intermediate risk
Included in the NOPHO ALL2008 protocol (July 2016 - February 2016)
Children (1-17,9 years at diagnosis)
You may not be if
ALL: high risk disease, ph-, genetic predisposition, bilinear ALL
\< 2 samples for asparaginase enzyme activity measurements